Inhibitor Therapeutics Stock

Inhibitor Therapeutics Equity 2024

Inhibitor Therapeutics Equity

5.28 M USD

Ticker

INTI

ISIN

US45720M1053

WKN

A2PQRT

In 2024, Inhibitor Therapeutics's equity was 5.28 M USD, a -36.34% increase from the 8.3 M USD equity in the previous year.

Inhibitor Therapeutics Aktienanalyse

What does Inhibitor Therapeutics do?

Inhibitor Therapeutics Inc is a biopharmaceutical company specializing in the development of innovative therapies for cancer and autoimmune diseases. The company was founded in the USA in 2008 and has since established itself as a leading player in the biotech industry. The history of Inhibitor Therapeutics Inc began with the discovery of a promising molecule called ITI-007, which could represent a novel treatment option for schizophrenia. After extensive preclinical tests and clinical studies, ITI-007 was eventually approved by the FDA and brought to market. The medication has proven to be very successful and is used by many patients worldwide. Today, Inhibitor Therapeutics Inc's business model includes several different divisions. In addition to schizophrenia therapy, the company focuses on the development of innovative cancer therapies based on the blockage of enzymes and proteins responsible for tumor growth. The company utilizes a wide range of technologies to develop the best therapies for different types of cancer. Inhibitor Therapeutics Inc's products also include a range of diagnostics and biomarkers that contribute to the early detection and treatment of cancer. These technologies enable personalized medicine and help improve the effectiveness of therapies. Overall, the goal of Inhibitor Therapeutics Inc is to improve the lives of millions of people through groundbreaking innovations in cancer and autoimmune therapy. The company works closely with leading scientific institutions and clinics to translate the latest research findings into clinical practice. An important part of Inhibitor Therapeutics Inc's corporate culture is promoting diversity and inclusion. The company actively strives to create a work environment that is open and inclusive, where every employee has the opportunity to reach their full potential. Overall, Inhibitor Therapeutics Inc is an emerging company specializing in the development of innovative therapies for cancer and autoimmune diseases. With a wide range of technologies and products, a strong corporate culture, and a dedicated team of employees, the company is well-positioned to continue growing in the coming years and make its vision of better health for all a reality. Inhibitor Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Inhibitor Therapeutics's Equity

Inhibitor Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Inhibitor Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Inhibitor Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Inhibitor Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Inhibitor Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Inhibitor Therapeutics stock

What is the equity of Inhibitor Therapeutics this year?

Inhibitor Therapeutics has equity of 5.28 M USD this year.

What was the equity of Inhibitor Therapeutics compared to the previous year?

The equity of Inhibitor Therapeutics has increased/decreased by -36.34% decreased compared to the previous year.

What impact does a high equity have on investors of Inhibitor Therapeutics?

A high equity is advantageous for investors of Inhibitor Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Inhibitor Therapeutics?

A low equity can be a risk for investors of Inhibitor Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Inhibitor Therapeutics affect the company?

An increase in equity of Inhibitor Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Inhibitor Therapeutics affect the company?

A reduction in equity of Inhibitor Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Inhibitor Therapeutics?

Some factors that can affect the equity of Inhibitor Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Inhibitor Therapeutics so important for investors?

The equity of Inhibitor Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Inhibitor Therapeutics take to change the equity?

To change equity, Inhibitor Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Inhibitor Therapeutics pay?

Over the past 12 months, Inhibitor Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Inhibitor Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Inhibitor Therapeutics?

The current dividend yield of Inhibitor Therapeutics is .

When does Inhibitor Therapeutics pay dividends?

Inhibitor Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Inhibitor Therapeutics?

Inhibitor Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Inhibitor Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Inhibitor Therapeutics located?

Inhibitor Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Inhibitor Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Inhibitor Therapeutics from 11/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/1/2024.

When did Inhibitor Therapeutics pay the last dividend?

The last dividend was paid out on 11/1/2024.

What was the dividend of Inhibitor Therapeutics in the year 2023?

In the year 2023, Inhibitor Therapeutics distributed 0 USD as dividends.

In which currency does Inhibitor Therapeutics pay out the dividend?

The dividends of Inhibitor Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Inhibitor Therapeutics

Our stock analysis for Inhibitor Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Inhibitor Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.